RxDoctor Payments Data

Guillermo Davila, MD

Obstetrics & Gynecology · Weston, FLNPI 1598727034

Payments from drug & device makers

$89,256in general payments, 2019–2025

Across 123 payments — averaging $725.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Femselect Inc.$44K
  • Boston Scientific$27K
  • Ferring Pharmaceuticals Inc.$7K
  • Acell, Inc.$5K
  • Caldera Medical, Inc$4K
  • LINA Medical USA Inc$2K
  • plus $2K from 9 others
$700in research payments, 2019–2025

Across 2 payments — averaging $350.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Femselect Inc.$700

What the payments were for

  • Consulting fees$23,86259%
  • Speaking & faculty fees$7,38718%
  • Travel & lodging$6,89117%
  • Food & beverage$2,1965%
  • Education$650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,256 in reported general payments places this provider in the 95th percentile of 2,438 obstetrics & gynecology providers in Florida.

See all obstetrics & gynecology providers in Florida

Medicare billing

Part B allowed, 2024
$337,775
Medicare patients
576
Services billed
3,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron52$42,498
Estradiol636$37,907
GemtesaVibegron22$16,913
Trospium Chloride122$10,785
Methenamine Hippurate112$9,187
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst170$2,151
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip88$1,714
Tamsulosin Hcl119$1,428
Clobetasol Propionate15$515
Imipramine Hcl32$419
Cyclobenzaprine Hcl97$330
Ibuprofen103$314
Doxycycline Monohydrate15$290
Tramadol Hcl119$287
Baclofen21$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$21$42,49852 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,438 obstetrics & gynecology providers in Florida.

Other obstetrics & gynecology in Weston

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →